A groundbreaking study led by researchers from MSH Medical School Hamburg, Charité – Universitätsmedizin Berlin, and a Hamburg-based startup shows how the body's own inner clock can influence the efficacy and tolerability of cancer therapies. The research, published in eBioMedicine, suggests that disruptions in circadian rhythm can exacerbate the side effects of treatment with PARP inhibitors. These findings could significantly shape the future of personalized cancer treatment by adapting therapy times to patients' biological rhythms.
Circadian Disruptions and Their Effects
The study, part of the Phase III clinical trial MAMOC, examined patients with ovarian cancer treated with PARP inhibitors such as Rucaparib. These drugs specifically block DNA repair in cancer cells and are a central component of modern cancer therapies. However, the researchers found that patients with disrupted circadian rhythms – the internal clock that controls processes like sleep, metabolism, and cell division – often experienced more severe side effects from the therapy. These circadian disruptions were directly linked to increased treatment toxicity, indicating that individual biorhythms influence treatment tolerability and possibly efficacy.
The investigation was led by Prof. Dr. Angela Relógio, Professor of Systems Medicine at MSH Medical School Hamburg, and Prof. Dr. Elena Ioana Braicu, Gynecological Oncologist at Charité. The project was supported by a network of hospitals in cities such as Berlin, Munich, Aachen, Karlsruhe, Krefeld, Dessau, Münster, Saarbrücken, and Wiesbaden. Using advanced analysis methods, including mathematical models and gene expression analyses, the researchers examined the effects of the therapy on approximately 800 genes, including key regulators of circadian rhythm like BMAL1 and PER2. These genes play a crucial role in controlling the inner clock and showed significant changes in the patients studied.
TimeTeller: Innovation for Precision Medicine
A central element of the study was the use of TimeTeller technology, developed by the startup of the same name, a spin-off from Charité currently based at MSH Medical School Hamburg. TimeTeller is an innovative tool that captures individual circadian rhythms in real-time by analyzing biological data, such as gene expression. This technology enabled a precise investigation of the interactions between cancer therapy and patients' biorhythms. The results show that circadian disruptions are not merely a side effect of therapy but actively influence treatment toxicity.
TimeTeller technology is a prime example of the connection between academic research and entrepreneurial innovation. By integrating circadian analyses into clinical studies, it opens up new possibilities for making cancer therapies more individualized. By adapting the administration of medications to the optimal biological time – an approach known as chronotherapy – side effects could be reduced and the effectiveness of the treatment increased. This approach takes into account that biological processes such as cell division or enzyme activity vary depending on the time of day, which can significantly influence the effect of medications.
Potential of Chronotherapy
The results of the study are a promising step towards personalized cancer treatment. By adapting therapy times to the circadian rhythm of patients, not only could side effects be minimized, but the effectiveness of the treatment could also be improved. Especially in ovarian cancer, a disease that often involves severe side effects, this could significantly improve the quality of life for those affected. Researchers see great potential in chronotherapy to further advance precision medicine by incorporating not only genetic markers but also biological timing into therapy planning.
Nevertheless, caution is advised. The researchers emphasize that chronotherapy does not promise a cure and further studies are necessary to validate the results and transfer them into clinical practice. The analysis of the circadian rhythm requires complex technologies and precise implementation, which still presents challenges in clinical routine. Nevertheless, the scientists are convinced that this approach can make existing therapies more tolerable and effective.
A Model for Interdisciplinary Collaboration
The study impressively shows how collaboration between science, clinics, and innovative startups can advance medical research. MSH Medical School Hamburg actively promotes this interdisciplinary approach by creating platforms for collaboration between academic research and entrepreneurship. TimeTeller is an example of how scientific findings can be translated into practical applications that directly benefit patients. The involvement of hospitals from all over Germany also underscores the importance of a national network to transfer research results into clinical practice.
Outlook on the Future
The findings of the study mark an important milestone in the development of personalized cancer therapies. The integration of circadian rhythm into treatment planning could sustainably change the way cancer therapies are conducted. While further research is needed to integrate chronotherapy into clinical practice, the results already offer a promising perspective for patients, especially those with ovarian cancer. The close integration of science, clinical practice, and technological innovation, as demonstrated in this study, shows how modern medicine can break new ground to make therapies more precise and patient-friendly.
(Source: MSH Medical School Hamburg/Charité – University Medicine Berlin)
